SEARCH

SEARCH BY CITATION

References

  • 1
    Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. 2005; 23: 20212.
  • 2
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 1996; 335: 86575.
  • 3
    Brieger J, Weidt EJ, Schirmacher P, Storkel S, Huber C, Decker HJ. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors. J. Mol. Med. 1999; 77: 50510.
  • 4
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 1999; 5: 296370.
  • 5
    Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 2005; 23: 102843.
  • 6
    Schoenfeld AR, Parris T, Eisenberger A et al. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 2000; 19: 58517.
  • 7
    Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (Suppl 5): v137v139.
  • 8
    Ljungberg B, Cowan N, Hanbury DC et al. Guidelines on renal cell carcinoma. European Association of Urology. Updated April 2010. [Cited 8 May 2012.] Available from URL: http://www.uroweb.org/gls/pdf/09_Renal_Cell_Carcinoma_LR%20II.pdf.
  • 9
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer v.2. 2010. [Cited 8 May 2012.] Available from URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  • 10
    Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009; 27: 331218.
  • 11
    Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus Interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010; 28: 214450.
  • 12
    Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 227181.
  • 13
    Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 358490.
  • 14
    Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010; 116: 425665.
  • 15
    Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 2010; 28: 213743.
  • 16
    Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010; 28: 10618.
  • 17
    Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 108496.
  • 18
    Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A. Optimising the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest. 2010; 28: 85664.
  • 19
    Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can. Urol. Assoc. J. 2007; 1: S41S54.
  • 20
    Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 2010; 10: 30517.
  • 21
    Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin. Genitourin. Cancer 2008; 6: S7S13.
  • 22
    Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin. Cancer Res. 2010; 16: 59237.
  • 23
    Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 2008; 14: 727283.
  • 24
    De Luca A, Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 2010; 13: 63645.
  • 25
    Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009; 48: 96470.
  • 26
    Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008; 118: 8495.
  • 27
    Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J. Biol. Chem. 2005; 280: 990412.
  • 28
    Yang R, Thomas GR, Bunting S et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 1996; 27: 83844.
  • 29
    Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 2007; 49: 18693.
  • 30
    Steeghs N, Hovens M, Rabelink A et al. VEGFR-2 blockade in patients with solid tumors: mechanism of hypertension and effects on vascular function. J. Clin. Oncol. 2006; 24: Abstract 3037.
  • 31
    van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J. Clin. Oncol. 2007; 25: 29935.
  • 32
    Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009; 297: R1R5.
  • 33
    Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann. Oncol. 2009; 20: 80715.
  • 34
    Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 2011; 103: 76373.
  • 35
    Escudier BJ, Ravaud A, Négrier S et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J. Clin. Oncol. 2008; 26 (Suppl): Abstract 5025.
  • 36
    Rini BI, Schiller JH, Freuhauf JP et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin. Cancer Res. 2011; 17: 38419.
  • 37
    Bhargava P, Esteves B, Al-Adhami M et al. Effect of hypertension, nephrectomy, and prior treatment on the efficacy of tivozanib (AV-951) in a phase II randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC). 2010. Presented at the 2010 ASCO Genitourinary Cancers Symposium; 5–7 March 2010: San Francisco, CA. Abstract 342.
  • 38
    Di Lorenzo G, Porta C, Bellmunt J et al. Toxicities of targeted therapy and their management in kidney cancer. Eur. Urol. 2011; 59: 52640.
  • 39
    Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma. Lancet Oncol. 2009; 10: 75763.
  • 40
    Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 12534.
  • 41
    Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 210311.
  • 42
    Pfizer Inc. Torisel® (temsirolimus), Summary of Product Characteristics. 2009.
  • 43
    Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008; 9: 11723.
  • 44
    Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009; 48: 917.
  • 45
    Rixe O, Dutcher JP, Motzer RJ et al. Association between diastolic blood pressure (DBP) ≥90 mmHg and efficacy in patients (pts) with metastatic renal cell carcinoma (mrRCC) receiving axitinib (AG-013736: AG). Ann. Oncol. 2008; 19 (Suppl 8): Abstract 587PD.
  • 46
    Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 201119.
  • 47
    F.Hoffmann-La Roche Ltd. Avastin® (bevacizumab), Summary of Product Characteristics. 2009.
  • 48
    Pfizer Inc. SUTENT® (sunitinib), Summary of Product Characteristics. 2009.
  • 49
    Choueiri TK, Schutz FA, Je Y et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 2010; 28: 22805.
  • 50
    Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009; 10: 96774.
  • 51
    Rini BI. Hypertension as a biomarker for anti-VEGF efficacy: incidence, mechanisms, and association with clinical outcome. Kidney Cancer J. 2011; 8: 10611.
  • 52
    Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2008; 26: 520412.
  • 53
    GlaxoSmithKline. Votrient® (pazopanib) Summary of Product Characteristics. 2011.
  • 54
    Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011; 378: 19319.
  • 55
    Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D. 2011; 11: 11326.
  • 56
    Chobanian AV, Bakris GL, Black HR et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 120652.
  • 57
    Mancia G, De BG, Dominiczak A et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J. Hypertens. 2007; 25: 175162.
  • 58
    Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28: 1462536.
  • 59
    Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006; 12: 90816.
  • 60
    Eschenhagen T, Force T, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011; 13: 110.
  • 61
    Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 2010; 55: 21320.
  • 62
    Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008; 29: 2388442.